|Bid||0.9800 x 3000|
|Ask||0.9850 x 800|
|Day's Range||0.9100 - 1.0500|
|52 Week Range||0.5500 - 5.4100|
|Beta (5Y Monthly)||2.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 07, 2020 - Aug 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.15|
NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Precipio, Inc. (NASDAQ:PRPO) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 19, 2020 at 5:00 PM Eastern ...
NEW HAVEN, Conn., May 15, 2020 -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its form 10Q for the period ending March 31st, 2020. Within the.
Specialty cancer diagnostics company Precipio, Inc. (PRPO), will be hosting its Quarter1-2020 corporate update call on Tuesday, May 19th at 5:00 PM ET. The conference call may be accessed by calling 844-695-5519 (international callers dial 1- 412-902-6760). All callers should ask for the Precipio Inc. conference call.
China Development Bank (CDB) Financial Leasing Co announced on Monday it had agreed with Boeing Co (BA) to cancel the purchase of 29 undelivered 737 MAX jets in the latest blow to the aerospace company.The move comes after the grounding of 737 MAX aircraft by aviation authorities worldwide and the suspension of 737 MAX aircraft deliveries by Boeing. Following the cancellation CDB Financial Leasing still has a total order of 70 undelivered Boeing 737 MAX jets under various purchase agreements. In addition, the two parties agreed that all Boeing 737 MAX 10 aircraft will be converted to Boeing 737 MAX 8 aircraft and that the delivery of another 20 undelivered jets will be deferred to dates in 2024, 2025 and 2026.“In light of evolving aviation market dynamics, we’ve been working together with Boeing over many months to re-calibrate our MAX orderbook to be in line with our long-term view of the market and related opportunities,” Xuedong Wang, chairman of CDB Financial unit CDB Aviation, said in a statement.The cancellation comes after General Electric’s (GE) aircraft leasing company GE Capital Aviation Services (GECAS) said on Friday it agreed with Boeing to scrap the order of 69 undelivered 737 MAX aircraft from GECAS’ orderbook. Following the agreement, GECAS maintains 29 MAX aircraft in its fleet and 82 on order, making it among Boeing’s largest lessor customers for this family of aircraft.“[The] agreement will help GECAS better align our available fleet with the needs of our global customer base,” GECAS President and CEO Greg Conlon said in a statement. “We remain fully committed to the 737 MAX program and our valuable, long-term partnership with Boeing.”Boeing shares advanced 15% on Friday to close at $154 as it said it plans this week to resume production at its Philadelphia plant, as well as, restart manufacturing of its commercial planes in Washington state.Read more: Boeing Plans to Resume Production Next WeekTipRanks data shows that Wall Street analysts, have a Moderate Buy consensus rating on Boeing’s stock based on 13 Holds and 6 Buys. The $187.11 average price target foresees a 22% upside potential for Boeing shares in the next 12 months. (See Boeing’s stock analysis on TipRanks). Related News: Boeing Shares Spike 15% on Plans to Resume Production Next Week United Airlines to Sell 22 Planes to Bank of China Aviation General Motors Secures $1.95 Billion Revolving Credit Line More recent articles from Smarter Analyst: * Despite Uncertainty, Apple Stock Still an Attractive Long-Term Bet * Microsoft Scores Five-Year Software Deal With Coca-Cola * Apple Delaying iPhone 12 Mass Production By One Month- Report * 2 5G Stocks to Consider as the Trend Heats Up
General Electric Co. (GE) said on Monday that it used part of the $20 billion in proceeds it generated from the sale of its biopharma business to reduce and refinance debt.As part of its deleveraging plan, General Electric said it repaid $6 billion of its loan to finance unit GE Capital on April 1, using proceeds of the biopharma sale. In addition, the industrial conglomerate announced that GE Capital is issuing a tender for up to $9 billion in debt securities maturing in 2020. Separately, GE Capital repaid $4.7 billion of debt maturing in the first quarter of this year, the company said.“With net proceeds of about $20 billion from the sale of BioPharma now in hand, we are taking swift actions to de-risk and de-lever our balance sheet and prudently manage our liquidity amid a challenging external environment,” said GE Chairman and CEO H. Lawrence Culp, Jr. “We continue to execute on our priorities, including solidifying our financial position by further reducing debt and improving our cash operations and management. We remain committed to achieving our leverage goals over time.”Read more: General Electric Closes Biopharma Sale to DanaherAs of March 31, 2020, GE had $47 billion in consolidated cash, cash equivalents, and restricted cash. As part of its financial management process, General Electric said it is also refinancing a back-up credit facility that expires in 2021.TipRanks data shows that Wall Street analysts are slightly cautious about recommending General Electric as 8 have a Buy rating on the stock and 7 have a Hold rating adding up to a Moderate Buy consensus rating. The average price target of $11.40 per share implies a 63% twelve-month gain, should the target be met. (See General Electric’s Stock Analysis on TipRanks).Last week, General Electric disclosed that it expects adjusted 1Q EPS to be “materially below” its prior guidance on March 4, 2020 of about $0.10, and withdrew financial guidance for 2020. However, investors were encouraged by the anticipation that General Electric sees industrial free cash flow to be near the prior guidance of about negative $2 billion, according to preliminary figures.General Electric is scheduled to hold its first-quarter earnings call on April 29.Related News: Ford Expects $600 Million Quarterly Loss Due to Coronavirus Shutdown S&P Cuts General Electric’s Credit Outlook to Negative Amid Debt Concern Honeywell Secures $1.5 Billion Revolving Credit Line More recent articles from Smarter Analyst: * Expedia On Cusp of Selling $1B Stake to Silver Lake, Apollo Global * Macy’s Seeks to Raise Up to $5 Billion in Debt - Report * Gilead, oNKo-innate Look To Natural Killer Cells For New Cancer Treatment * Chipotle 1Q Sales Rise Fueled By Record Digital Sales Growth
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ Reagent Rental (HSRR) program. A tried-and-true structure that is prevalent in the diagnostic world, the HSRR program will enable office-based physicians to place Real-Time PCR (RT-PCR) testing equipment with no capital outlay. Through this program, the physician practice will have the ability to run the diagnostic tests in-house instead of sending out to reference laboratories, obtaining faster results and providing patients with better care.
Like many companies, our first priority is to protect our employees and families, so we have instituted a policy that allows only essential employees to come to our offices. For better or worse, I suppose cancer patients have more to worry about than COVID-19, and we are here to make sure we have their backs. Fortunately, as members of the healthcare community and as a certified laboratory, we already follow strict sanitary precautions.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has completed the non-cash transaction of the transition of Oncometrix’s customer base, as discussed in Precipio’s recent announcement. As stated previously, the transaction with Poplar involves no exchange of cash or equity in consideration, providing non-dilutive impact to shareholders.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that preliminary results from its artificial intelligence (AI) initial MVP (Minimal Viable Product) model demonstrate a profound clinical value. The diagnosis of hematopoietic diseases (via the analysis of bone marrow and peripheral blood samples) has always suffered from an inherent systemic flaw, stemming from the expectation that oncologists provide a clinical suspicion upon submitting a biopsy for diagnosis. The clinical suspicion determines the pathway of diagnosis, and is the sole driver for the laboratory in its testing selection, intended to confirm/rule out the oncologist’s clinical suspicion.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it is in advanced discussions with Poplar Healthcare to establish a strategic partnership that includes, among other transactions, the acquisition of the customer base of Poplar’s Hematopathology division, OncoMetrix. The planned transaction contemplates that Precipio will assume responsibility for OncoMetrix's customer base and associated revenues of approximately $3M (as of YE 2019, unaudited). This will represent a potential doubling of Precipio’s current pathology services revenue, and should provide a substantial improvement to Precipio's laboratory economies of scale, resulting in increased gross margins.
TrialJectory, an AI-powered technology platform that empowers cancer patients to search and match with clinical trials, removing barriers to advanced treatment options, today announced that the Company has launched a new partnership with specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) to provide cancer patients worldwide with a first-of-its-kind diagnostic and clinical trial-matching service that assists doctors in providing the best possible treatment for their patients.
The management team of Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), would like to provide an explanation on the recent Amendment to the S-1 that was filed yesterday, on January 27, 2020. The company filed its S-1 registration statement for the equity line by Lincoln Park on January 14, 2020. The company received the SEC's confirmation of no-review, however, the SEC requested that the company add a table with its executive compensation updated as of December 31, 2019.
Yesterday’s filing was only for the registration (not sale) of the final tranche of the $10M equity line financing vehicle facilitated by Lincoln Park Capital. This $10M equity line transaction was previously announced in the company’s 8-K filing on September 7, 2018 and approved by shareholders on December 20, 2018. In order to utilize the equity line, the company is required to register all shares in advance.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on Monday, January 20th at 5pm it will conduct a shareholder update call with regard to several strategic initiatives for 2020 as well as the current status of IV-cell and Hemescreen deployment and the diversification of our business model into the products sector. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760).
NEW HAVEN, CT / ACCESSWIRE / December 17, 2019 / Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the receipt of their first commercial order for IV-Cell from Northwell Health. Precipio estimates generating considerable six-figures in annual revenues to the company as the first midsize customer to adopt IV-Cell. Northwell Health is New York's largest private employer and health care provider, with a $12B operating budget, 23 hospitals and more than 750 outpatient facilities; and serving over 5.5 million patients annually.
NEW HAVEN, CT / ACCESSWIRE / December 4, 2019 / Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced the resignation of Samuel Riccitelli from the board of directors, and his replacement by Richard Sandberg. The transition was ratified at the company's recent board of directors meeting and is effective as of December 1st, 2019. Mr. Riccitelli decided to resign so that he can focus on his recently accepted position as the Chief Executive Officer of Pathnostics, a diagnostics company focused on improving antibiotic stewardship through better diagnosis and treatment selection for patients suffering from urinary tract infections.
NEW HAVEN, CT / ACCESSWIRE / November 14, 2019 / Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced a substantial biomarker project with a large healthcare company that will generate significant revenue over the next two quarters. Precipio expects the project to be completed by the end of Q1 2020. "We are pleased to see companies in the pharma sector continuing to value the testing expertise and technologies that Precipio can offer," said Stephen Miller, Precipio's Chief Commercial Officer.
NEW HAVEN, CT / ACCESSWIRE / November 14, 2019 / Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced preliminary results shared by two independent laboratories conducting testing of IV-Cell Media in a side-by-side parallel study comparing it to the media currently used by these laboratories. Both laboratories conducted a multi-sample study to evaluate the clinical and operational performance of IV-Cell, as part of their assessment to convert to using IV-Cell exclusively.
NEW HAVEN, CT / ACCESSWIRE / November 4, 2019 / Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its Third Quarter 2019 corporate update call on Wednesday, November 13th at 5:30 PM ET. The conference call may be accessed by calling 844-695-5519 (international callers dial 1- 412-902-6760). All callers should ask for the Precipio Inc. conference call.
Partners physicians are teaching affiliates of Harvard Medical School, and Partners is a national leader in biomedical research. Partners Online Second Opinions is part of Partners HealthCare, a not-for-profit healthcare delivery network based in Boston, Massachusetts.
NEW HAVEN, CT / ACCESSWIRE / October 2, 2019 / Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), will hold a shareholder update call where CEO Ilan Danieli will discuss the company's commercial progress. The conference call may be accessed by calling 1-844-695-5519 (international callers may dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as its molecular testing assay for hematologic malignancies such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPD). TN Oncology’s laboratory has validated the test and will be performing the HemeScreen assay as a lab developed test (LDT) within their laboratory.
Despite early hopes to the contrary, it looks as though September is going to end up as a relatively flat month for my trading account. Although there was some strong action coming out of August that carried ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Micron Technology, Inc. (NASDAQ: MU ) shares ...
This includes extensive testing as well as side-by-side comparison to the laboratory’s existing process in order to ensure both consistent results, as well as superior performance of the products. Only once these and other important parameters are demonstrated, does a laboratory proceed to discuss purchasing this product and integrating it into their clinical operations. In the laboratories that have completed their clinical testing step, the next and final step is the agreement on commercial terms.